Serina Therapeutics, Inc.
SER
$1.56
-$0.08-4.60%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 132.14% | -96.33% | -95.90% | -98.37% | -98.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 132.14% | -96.33% | -95.90% | -98.37% | -98.22% |
| Cost of Revenue | 75.87% | 101.25% | 158.50% | 201.29% | 213.23% |
| Gross Profit | -75.44% | -318.95% | -935.93% | -28,203.03% | -1,070.46% |
| SG&A Expenses | 34.97% | 45.50% | 110.71% | 236.58% | 255.03% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.54% | 71.69% | 133.11% | 218.43% | 233.72% |
| Operating Income | -54.26% | -126.61% | -258.14% | -561.44% | -917.78% |
| Income Before Tax | -71.29% | -151.63% | -79.86% | 91.11% | -312.70% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -71.46% | -151.63% | -79.86% | 91.11% | -312.70% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -50.00% | -16.67% | 129.63% | -- | -- |
| Net Income | -72.17% | -152.87% | -79.67% | 91.77% | -311.44% |
| EBIT | -54.26% | -126.61% | -258.14% | -561.44% | -917.78% |
| EBITDA | -55.74% | -128.93% | -264.56% | -578.97% | -967.92% |
| EPS Basic | 60.93% | 54.42% | 63.48% | 99.38% | -307.00% |
| Normalized Basic EPS | 15.24% | -26.43% | 41.80% | 104.99% | -438.02% |
| EPS Diluted | 61.85% | 58.41% | 70.49% | 96.85% | -823.35% |
| Normalized Diluted EPS | 19.83% | 12.30% | 48.21% | 100.56% | -4,075.07% |
| Average Basic Shares Outstanding | 39.27% | 73.76% | 137.17% | 278.87% | 227.36% |
| Average Diluted Shares Outstanding | 24.23% | 28.74% | 45.19% | 61.91% | 8.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |